Sequent Extended Study
Recruiting
Observational Study
Coronary Artery Disease
Ischemic Heart Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 2,028 (estimated)
- Sponsor
- Fundación EPIC · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Sequent Please Neo to meet EU Medical Device regulation (MDR) requirements in all the consecutive patients treated with Sequent Please Neo.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients treated with Sequent please neo according to routine hospital practice and following instruction for use.
* Informed Consent Signed.
Exclusion Criteria:
* Patient life expectancy less than 12 months.
* Contraindication for antiplatelet therapy.
* Not meet inclusion …
Contacts